Climate Change Data

Environmental Metrics

ESG Focus Areas

• Environment
• Social
• Governance

Environmental Achievements

• Ongoing focus on energy conservation, waste minimisation and safe materials handling
• Singapore R&D facility adheres to good laboratory practices and standards

Social Achievements

• Diversity Policy reflects equitable treatment of people irrespective of age, gender, ethnicity, religious beliefs and disabilities
• Support for freedom of association and human rights
• Promotion of work-life balance
• Support for personal development with training programs

Governance Achievements

• Corporate Governance Policy complies with Australian Securities Exchange recommendations
• Code of ethics and conduct in accordance with company values
• Transparency and accountability on remuneration
• Effective audit and internal controls
• Appropriate business ethics

Climate Goals & Targets

Environmental Challenges

• Brexit and its impact on EU distribution of SCENESSE®
• Implementation of the Falsified Medicines Directive (FMD)
• Maintaining supply chain and ensuring product supply for patients amidst Brexit uncertainty
• Managing increased financial demands while maintaining profitability

Mitigation Strategies

• Established a new European subsidiary in Ireland to hold marketing authorisation and manufacturing license
• Appointed an alternate manufacturing partner to fulfil EU regulations
• Redesigned pharmacovigilance system
• Sought direct dialogue with European Commission to address FMD concerns
• Consistently invested in UK staff and infrastructure
• Maintained operational costs below budget

Supply Chain Management

Responsible Procurement

• Supplier standards on environmental issues
• Supplier standards on ethical behavior

Climate-Related Risks & Opportunities

Reporting Standards

Frameworks Used: Australian Securities Exchange Corporate Governance Council’s Corporate Governance Principles and Recommendations, 3rd Edition

Third-party Assurance: Grant Thornton Australia Limited

Environmental Metrics

ESG Focus Areas

• Sustainability
• Growth
• Profitability

Social Achievements

• Facilitating treatment access to SCENESSE® for EPP patients worldwide

Governance Achievements

• Prudent management of expenditures
• Focus on long-term strategy resulting in five consecutive annual profits

Climate Goals & Targets

Environmental Challenges

• COVID-19 pandemic affecting supply chain
• Competition for products
• Regulatory approvals and label claims
• Currency fluctuations and restrictions
• Healthcare regulation and pharmaceutical pricing and reimbursement reforms
• Environmental risks

Mitigation Strategies

• Prudent risk management
• Disciplined implementation of long-term strategy
• Highly integrated business model
• Building cash reserves sufficient to self-finance planned organic growth

Supply Chain Management

Climate-Related Risks & Opportunities

Sustainable Products & Innovation

• SCENESSE® (afamelanotide 16mg)
• PRÉNUMBRA®
• NEURACTHEL®
• CUV9900
• Phimelanotide
• Parvysmelanotide